Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma

BACKGROUND: This study assessed the safety, tolerability, pharmacokinetics and pharmacodynamics of the first-in-class dual mammalian target of rapamycin complex (mTORC)1/mTORC2 inhibitor, AZD8055. METHODS: Patients with advanced solid malignancies or lymphomas were recruited into this phase I, open-...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Naing, A, Aghajanian, C, Raymond, E, Olmos, D, Schwartz, G, Oelmann, E, Grinsted, L, Burke, W, Taylor, R, Kaye, S, Kurzrock, R, Banerji, U
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Nature Publishing Group 2012
Konular:
Translational Therapeutics
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3461162/
https://ncbi.nlm.nih.gov/pubmed/22935583
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2012.368
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller